SICHUAN BAILI PHARM CO LTD has a total of 34 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2011. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are BERLIN-CHEMIE AG, BERLIN CHEMIE AG and JACKSON SIMON MARK.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 12 | |
#2 | Australia | 5 | |
#3 | Canada | 5 | |
#4 | EPO (European Patent Office) | 5 | |
#5 | Singapore | 5 | |
#6 | Israel | 1 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Zhu Yi | 33 |
#2 | Li Jie | 32 |
#3 | Wan Weili | 29 |
#4 | Zhuo Shi | 29 |
#5 | Yu Yongguo | 24 |
#6 | Wang Yiqian | 10 |
#7 | Wang Yixi | 8 |
#8 | Liu Weijia | 8 |
#9 | Chen Lan | 6 |
#10 | Li Gangrui | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019047941A1 | Amanitin antibody conjugate | |
CA3095071A1 | Non-natural amatoxin-type antibody conjugate | |
WO2019034176A1 | Camptothecin-antibody conjugate | |
WO2019034179A1 | Indole ido inhibitor and method for preparing the same | |
CA3095067A1 | An antibody-drug conjugate having an acidic self-stabilization junction |